SCHEMBL648672

SCHEMBL648672

O=C1N/C(=N/c2ccc(Cl)cc2Cl)S/C1=C\c1cnc(NCCCN2CCOCC2)s1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC25A P30304 1/20 0.43
CDC25B P30305 1/20 0.43
ITGB2 P05107 1/20 0.39
ICAM1 P05362 1/20 0.39
ITGAL P20701 1/20 0.39
GSK3B P49841 1/20 0.39
MAPK1 P28482 4/20 0.39
MAPT P10636 3/20 0.39
PKM P14618 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
LMNA P02545 2/20 0.39
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 1/20 0.39
IDE P14735 1/20 0.39
HPGD P15428 1/20 0.39
HTT P42858 1/20 0.39
USP2 O75604 1/20 0.38
FGFR1 P11362 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL649998 1.00 CDC25A (0.43) CDC25ACDC25BITGB2ICAM1ITGAL
SCHEMBL650930 0.87 MAPT (0.48) MAPK1MAPTPKMMEN1KMT2A
SCHEMBL650929 0.87 MAPT (0.48) MAPK1MAPTPKMMEN1KMT2A
SCHEMBL650124 0.85 KMT2A (0.42) CDC25BMAPK1MAPTPKMMEN1
SCHEMBL650125 0.85 KMT2A (0.42) CDC25BMAPK1MAPTPKMMEN1
SCHEMBL10227930 0.80 MAPT (0.42) CDC25BMAPK1MAPTPKMMEN1
SCHEMBL652003 0.80 MAPT (0.42) CDC25BMAPK1MAPTPKMMEN1
SCHEMBL652004 0.80 MAPT (0.42) CDC25BMAPK1MAPTPKMMEN1
SCHEMBL653818 0.80 NPC1 (0.47) GSK3BMAPTMEN1KMT2ALMNA
SCHEMBL653819 0.80 NPC1 (0.47) GSK3BMAPTMEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed
WO-2010122979-A1 THIAZOLIDINONE DERIVATIVE SBIバイオテック株式会社 (JP) 2010-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE CDC7, CDK17, CDCA2 CDC25A 78/4885CDC25B 59/4885ITGB2 3992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.